New lung drug put to the test: will it harm the heart?

NCT ID NCT06107036

Completed Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 trial tested whether a single dose of the experimental drug BI 1015550 (nerandomilast) affects the heart's electrical activity in 46 healthy adults. Participants received low and high doses of the drug, a placebo, and an open-label heart-safe drug (moxifloxacin) for comparison. The goal was to see if BI 1015550 causes any dangerous changes in heart rhythm, which is important for future studies in patients with lung conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 1015550 (nerandomilast)
What this could lead to: If the drug shows no heart risks, it could support safer use in future trials for conditions like lung fibrosis.
What could go wrong: This is an early safety study in healthy people, not patients. It cannot predict if the drug works for any disease or if rare heart effects appear later.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Quotient Sciences

Nottingham, NG11 6JS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.